Abstract
N′-Nitrosonornicotine (NNN) is present in significant quantities in tobacco and tobacco smoke and is believed to play an important role as a cause of cancer in people who use tobacco products. Biomarkers of NNN uptake in humans such as urinary metabolites would be useful for assessing cancer risk. Previous studies, carried out almost exclusively in rodents, have characterized urinary metabolites of NNN, but none of these would be suitable as a biomarkers of NNN uptake in humans. Therefore, we studied NNN metabolism in the patas monkey. Monkeys were treated intravenously with [5-3H]NNN, which has tritium in the pyridine ring. Blood and urine samples were collected at timed intervals. Six urinary metabolites were observed by high-performance liquid chromatography (HPLC) and were identified by their spectral properties and/or comparison to appropriate standards as follows: metabolite (% of radioactivity eluting from HPLC ± S.D.,n = 3 monkeys); 4-hydroxy-4-(3-pyridyl)butyric acid (43.8 ± 4.0); 4-oxo-4-(3-pyridyl) butyric acid (2.7 ± 0.66); norcotinine (13.1 ± 2.7); norcotinine-1N-oxide (16.5 ± 1.3); 3′-hydroxynorcotinine (16.9 ± 2.0); 3′-(O-β-d-glucopyranuronosyl)hydroxynorcotinine (5.4 ± 1.0); and unchanged NNN (0.63 ± 0.15). The two major metabolites in serum were 4-hydroxy-4-(3-pyridyl)butyric acid and norcotinine. NNN was rapidly metabolized to 4-hydroxy-4-(3-pyridyl)butyric acid, whereas the formation of norcotinine and 3′-hydroxynorcotinine were somewhat delayed. The results of this study demonstrate substantial differences between NNN metabolism in the rodent and patas monkey. Metabolism of NNN to norcotinine and its derivatives was far more prevalent in the patas monkey than in the rat. 3′-Hydroxynorcotinine and itsO-glucuronide may be formed from NNN via α-oximinonornicotine or isomyosmine. There was no evidence that it was formed via norcotinine, although this pathway could not be excluded. 3′-Hydroxynorcotinine could potentially be a biomarker of NNN uptake in humans.
Footnotes
-
This study was supported by Grants CA-44377 and CA-81301 from the National Cancer Institute
- Abbreviations used are::
- NNN
- N′-nitrosonornicotine
- NNK
- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
- NNN-N-oxide
- N′-nitrosonornicotine-1-N-oxide
- keto alcohol
- 4-hydroxy-1-(3-pyridyl)-1-butanone
- keto acid
- 4-oxo-4-(3-pyridyl)butyric acid
- diol
- 4-hydroxy-4-(3-pyridyl)-1-butanol
- lactol
- 2-hydroxy-5-(3-pyridyl)tetrahydrofuran
- hydroxy acid
- 4-hydroxy-4-(3-pyridyl)butyric acid
- lactone
- 5-(3-pyridyl)tetrahydrofuran-2-one
- HPLC
- high-performance liquid chromatography
- MS
- mass spectometry
- GC
- gas chromatography
- CI
- chemical ionization
- MS/MS
- tandem mass spectometry
- PBS
- phosphate-buffered saline
- AUC
- area under the curve
- Received February 2, 2002.
- Accepted July 1, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|